$149.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Cagrilintide 10mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Cagrilintide 10mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 1415456-99-3 |
|---|---|
| Sequence | {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH₂ (Disulfide bridge: Cys2-Cys7) |
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Purity | ≥99% |
| Molecular Weight | Approximately 4409.01 g/mol |
| Applications | Obesity research, appetite regulation studies, type 2 diabetes research |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
Researchers evaluating where to buy Cagrilintide for research should begin with compound identity, batch documentation, analytical verification, and clear research-use-only positioning. Cagrilintide is discussed in scientific literature as a synthetic, long-acting amylin analogue with activity at amylin and calcitonin receptor systems, but that literature must remain separate from product-use claims for RUO materials [1] [2]. This product-page guide is written for laboratory buyers, technical procurement teams, and qualified research settings reviewing Cagrilintide peptide documentation.
To buy Cagrilintide for research, review whether the product listing, RUO label, certificate of analysis, purity data, identity verification, lot number, and handling and storage documentation are consistent. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published literature should be treated as scientific context, not product-use guidance.
The phrase buy cagrilintide can carry broad commercial intent, so a research product page should reframe it as buy Cagrilintide for research. That shift keeps the page focused on procurement review, compound identity, and documentation rather than consumer-facing claims.
For Pure Lab Peptides, the safer commercial question is not what a product does for a person. The safer question is whether qualified research buyers can evaluate the peptide supplied through clear documentation, analytical testing, and research-use-only labeling.
The first documents to review are the product listing, certificate of analysis, and batch-specific records. These materials should help confirm the compound name, lot number, testing method, purity statement, and identity-supporting data.
A COA is stronger when it connects directly to a specific lot. A general purity claim is less useful when it is not tied to batch details, test date, and method information.
RUO labeling helps define the intended research context for the material. FDA guidance on RUO labeling for in vitro diagnostic products emphasizes that labeling and promotion should remain consistent with research-only intent, which is a useful compliance principle for research product pages even when the product category differs [6].
For product-page copy, RUO clarity should appear before commercial language. Procurement teams should be able to see that the page is written for laboratory research, not personal use.
Cagrilintide is listed in PubChem with the molecular formula C194H312N54O59S2 and a computed molecular weight of about 4409 g/mol [1]. DrugBank identifies Cagrilintide under accession DB18887, and the IUPHAR/BPS Guide to Pharmacology describes it as a calcitonin-family receptor ligand with amylin and calcitonin receptor activity [7] [2].
In peptide research, that identity context matters because molecular weight, formula, receptor family, and peptide structure all help researchers evaluate whether a listing aligns with the published compound record.
Cagrilintide is a synthetic peptide and a structural analogue of amylin, a peptide hormone class studied through calcitonin-family receptor systems [2] [8]. Amylin receptor biology involves complexes formed by the calcitonin receptor and receptor activity-modifying proteins, which create multiple receptor subtypes [8].
For RUO product review, these points should remain classification details. They are useful for literature mapping and identity review, not for product claims.
Published medicinal chemistry literature describes Cagrilintide as a lipidated, long-acting amylin analogue developed through structural modifications that affect receptor interaction and stability-related properties in the research literature [3]. The Guide to Pharmacology similarly characterizes Cagrilintide as a nonselective agonist of amylin and calcitonin receptors [2].
A product-page research guide should treat these characteristics as literature context. They do not replace COA review, LC-MS identity support, or lot-specific verification.
Published literature has examined Cagrilintide in receptor pharmacology, metabolic pathway models, and broader amylin analogue research [2] [3] [9]. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
This distinction protects both scientific accuracy and product-page compliance.
Cagrilintide belongs in a metabolic pathway research lane because the literature connects amylin and calcitonin receptor systems with energy homeostasis models and receptor signaling investigations [2] [8]. The RUO-safe framing is pathway research, receptor biology, and model-specific interpretation.
This page does not position Cagrilintide for wellness, personal outcomes, or product performance. It positions the compound as a research material requiring documentation.
Same-lane entities include amylin, calcitonin receptor systems, GLP-1 receptor agonists as neighboring literature context, and receptor signaling models [2] [9]. Structural research has examined Cagrilintide binding across amylin receptor subtypes and calcitonin receptor complexes [9].
For product-page purposes, same-lane mapping helps researchers understand why certain databases, receptor resources, and peer-reviewed studies are relevant to the compound.
Pathway relevance does not mean a product claim. A receptor pathway can be scientifically relevant to a compound while still being inappropriate as marketing language for an RUO product.
Terms related to product effects or clinical outcomes can drift into claim territory when separated from model-specific literature. A compliant RUO product page should bring the discussion back to compound identity, published context, COA review, analytical testing, and lot documentation.
Model-specific findings depend on experimental design, endpoint selection, assay system, species, and study context. Published research can support scientific background, but it cannot convert an RUO material into a consumer, medical, or clinical product.
A safe literature interpretation asks: what model was used, what was measured, and what limitation applies? That framework keeps Cagrilintide peptide research grounded.
A Cagrilintide research peptide listing should make the documentation path easy to review. The key records include the product name, catalog specification, lot number, COA, purity method, identity-supporting method, label, and storage notes.
Researchers evaluating Cagrilintide 10mg or Cagrilintide 5mg listings should treat those terms as catalog identifiers only. They should not be interpreted as research directions or product-use instructions.
A useful product listing should identify the compound clearly and align with batch documentation. The name Cagrilintide, any listed amount, lot-specific COA, and RUO labeling should be consistent across records.
Product pages should also avoid unsupported scientific statements. When receptor or pathway claims appear, they should be backed by credible literature and separated from product positioning.
Catalog amounts describe the supplied material listing. They are not study instructions, exposure conditions, or recommended quantities.
This matters because product-page SEO can accidentally blur procurement language with product-use language. A safer page uses Cagrilintide 10mg only as a catalog specification and keeps all research interpretation tied to documentation and literature.
Clear labeling supports traceability. It helps technical procurement teams connect the product listing to the COA, lot number, batch record, and internal laboratory record.
Labels should not carry consumer-facing statements. They should support research material identification, not promotional claims.
Cagrilintide is described in receptor pharmacology resources as a ligand within the calcitonin-family receptor system, including amylin and calcitonin receptors [2]. Amylin receptors are formed by calcitonin receptor components with receptor activity-modifying proteins, creating receptor subtypes that appear in peptide research literature [8].
This receptor context helps define the research lane. It should not be used as a product claim.
Receptor signaling literature can support statements about what researchers have examined, which receptor systems are relevant, and how the compound is classified in pharmacology databases. Structural work published in 2025 examined Cagrilintide-bound active amylin receptor and calcitonin receptor complexes, adding molecular detail to the receptor-binding literature [9].
That kind of evidence supports pathway context. It does not support consumer-facing copy.
Amylin analogue research often compares native amylin, modified analogues, receptor interactions, and compound design [3] [8]. Cagrilintide is one example in this research lane.
For an RUO article, the focus should stay on scientific classification. It should not become a use case for people or animals.
Related peptides and receptor agonists can help researchers place Cagrilintide in a same-lane literature map. Pramlintide, amylin, calcitonin, and GLP-1 receptor agonists may appear in academic discussions, but each belongs to a distinct evidence and regulatory context [8] [10].
The safe product-page approach is to mention related peptides only as literature context. Related compounds should not create comparison claims for RUO materials.
A research-use-only product page should explain literature carefully. Studies may examine receptor interactions, structural dynamics, model endpoints, or analytical properties, but a product page should not translate those findings into claims about product performance.
For Cagrilintide, the most useful interpretation framework is evidence type, model context, limitation, and documentation relevance.
Study context can show how researchers investigated a pathway, receptor, or compound class. It cannot show what an RUO product is intended to do.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Formula, molecular weight, database classification [1] | Official database | Supports identity review, not product claims |
| Receptor context | Amylin and calcitonin receptor activity [2] | Pharmacology database | Supports literature mapping |
| Structural biology | Receptor-bound Cagrilintide complexes [9] | Peer-reviewed structural study | Supports mechanism context |
| Analytical review | HPLC and mass spectrometry methods for peptides [4] [5] | Analytical literature | Supports documentation review |
Research model design determines what a study can support. A receptor assay, structural study, in vitro model, preclinical model, and human study setting each answers a different kind of question.
Product pages should not collapse those categories into one claim. The more careful approach is to identify the model and state the limitation clearly.
A practical evidence ladder for Cagrilintide review starts with official databases, then receptor pharmacology resources, then peer-reviewed mechanistic literature, then broader review articles. Each source type contributes different value.
Official databases help with identity. Peer-reviewed studies help with pathway context. COA and analytical data help with batch-level product review.
Claim boundaries keep product pages accurate. They separate what scientific literature examines from what a research-use-only product page can say.
A Cagrilintide product page can discuss published literature, receptor context, COA review, purity testing, and identity verification. It should not turn scientific literature into consumer outcomes, therapeutic language, or clinical-use positioning.
Study findings belong to the study conditions. Product claims belong to product positioning. RUO pages should not merge the two.
If a study examines receptor systems, the product page can say that literature examines those receptor systems. It should not state or imply that the product produces a specific outcome.
Research copy should keep returning to the same documentation anchors: compound identity, certificate of analysis, analytical method, lot number, label, and storage record. These are the practical review points for technical procurement.
That focus also keeps commercial intent safer. Researchers evaluating where to buy Cagrilintide peptide for research need documentation, not consumer-facing promises.
Product-page language should keep clinical research, product effects, and product performance separate from RUO positioning. Those terms can become claims when presented without model context.
A safer page states what documentation exists, what literature category is relevant, and what the material is intended for: laboratory research use only.
A certificate of analysis is one of the most important records for research peptide procurement. It should identify the compound, lot, test method, reported purity, test date, and responsible laboratory or testing source.
A COA does not remove the need for scientific review. It gives procurement teams a batch-specific document to compare against the listing and label.
COA documentation should identify the compound name, lot number, and analytical method. If purity is reported, the method used to determine that purity should be visible.
For peptides, chromatography can help separate peptide material from related components, while mass spectrometry can support molecular identity review [4] [5].
Batch-specific documentation helps connect a physical research material listing to a test record. Without lot-level alignment, a COA may be difficult to interpret for procurement review.
The best practice is simple: the lot on the label, the lot on the COA, and the lot in the laboratory record should match.
COA dates help researchers understand when testing occurred. Lot details help determine whether the document applies to the material under review.
A current-looking page with an unrelated or outdated COA is less useful than a batch-specific record with clear matching details.
Purity and identity are related, but they are not the same. HPLC is widely used in peptide analysis because it can separate peptide components and support purity review through chromatographic data [4].
Mass spectrometry can add identity support by evaluating mass-related information, and USP has described mass spectrometry, NMR, and chromatography as methods that can support synthetic peptide quality assessment [5].
HPLC separates sample components under defined chromatographic conditions. In peptide analysis, reversed-phase HPLC is commonly used because it can resolve peptide-related material and produce chromatograms for purity assessment [4].
For procurement review, the key question is whether the purity statement is tied to a method and a batch. A standalone percentage is not enough.
LC-MS combines liquid chromatography with mass spectrometry, allowing researchers to connect separation behavior with mass-based identity information. High-resolution LC-MS methods have been used for qualitative and quantitative characterization of peptide materials and related impurities [11].
For Cagrilintide, LC-MS documentation can support identity review when it aligns with the expected molecular record and batch details.
Analytical data adds a technical layer to supplier evaluation. It helps reviewers compare the compound name, purity method, identity method, lot number, and COA date.
ICH Q2(R2) describes validation concepts for analytical procedures, including specificity, accuracy, precision, and other performance characteristics used to assess whether a procedure is suitable for its intended analytical purpose [12].
Handling and storage documentation should describe how the material is to be maintained in a laboratory setting. For lyophilized peptide materials, storage records often focus on temperature control, light exposure, moisture control, and batch tracking.
These notes are documentation requirements. They are not product-use instructions.
A lyophilized peptide or lyophilized powder form is a common research material format. The documentation should identify the material state clearly so the receiving laboratory can log it correctly.
For RUO procurement, the most important point is consistency. The product listing, label, and laboratory record should all describe the material in the same way.
Light and moisture can be relevant storage factors for laboratory materials. If a supplier provides storage notes, the lab record should capture those notes in a controlled documentation system.
The purpose is traceability and material integrity review. It is not consumer guidance.
Storage notes should describe laboratory handling conditions. They should not imply product readiness, personal use, or any outcome.
A strong RUO page keeps storage language technical. It avoids any suggestion that the reader is being guided toward use outside laboratory research.
Supplier documentation should make technical review easier, not harder. A research buyer should be able to compare product-page details, COA details, label details, and batch details without guessing.
For Cagrilintide, this includes the compound name, Cagrilintide peptide listing, certificate of analysis, analytical testing references, purity statement, and lot-specific verification.
Research buyers should compare whether each supplier provides RUO labeling, COA access, lot traceability, analytical method information, and consistent naming. Marketing claims should not outweigh documentation.
A supplier documentation matrix can include five simple columns: listing detail, COA detail, analytical method, lot record, and storage documentation.
Labeling consistency reduces uncertainty. If a label identifies the compound one way and the COA identifies it another way, procurement teams should resolve that mismatch before internal logging.
Consistency also supports future review. A clear laboratory record can show what was ordered, what was received, and which document supported it.
Third-party verification can add confidence when the testing source is clearly identified and the COA is tied to a specific lot. It is most useful when the method, date, and batch details are visible.
Verification should be treated as a documentation strength, not a guarantee beyond the limits of the reported method.
Related peptides in research help build a same-lane literature map. For Cagrilintide, related context may include amylin, calcitonin receptor systems, pramlintide, and GLP-1 receptor agonists as academic reference points [8] [10].
The purpose is not to rank compounds for personal outcomes. The purpose is to organize scientific context.
Same-lane peptides help researchers find relevant receptor families, pathway terms, and analytical expectations. For example, Cagrilintide and amylin analogue literature can point readers toward calcitonin-family receptor resources [2] [8].
This mapping supports research literacy. It should not create product comparisons based on consumer outcomes.
GLP-1 receptor agonists appear in the broader metabolic research landscape and in some literature discussing combination research settings. This context should be handled carefully because it can drift toward clinical-use language if presented as product positioning.
For an RUO page, GLP-1 receptor agonists are best treated as same-lane literature context, not as a claim about Cagrilintide products.
Related peptides should not be used to imply that one research material will behave like another in a product setting. Even compounds in a similar research lane can differ in receptor activity, structure, analytical profile, and evidence base.
The safe comparison is documentation-based: identity record, COA, purity method, verification method, and lot traceability.
Research peptide pages can be misunderstood when commercial search intent is mixed with scientific terminology. A safe page should correct those misunderstandings directly.
The goal is not to remove commercial clarity. The goal is to make commercial clarity research-specific.
Commercial terms are acceptable when they are tied to research procurement. The phrase buy Cagrilintide for research is safe because it defines the intended setting.
The standalone phrase buy Cagrilintide is less precise. It should be avoided as a product-page positioning phrase unless it is immediately framed for laboratory research.
Product amounts such as 10mg or 5mg should not become separate SEO targets when the canonical topic is Cagrilintide. They are catalog details.
A canonical product-page article should focus on Cagrilintide as the compound, not on variant-specific intent.
Researchers should not infer product claims from listing language. A listing can identify the compound, amount, purity, and documentation, but it should not imply outcome claims.
The safer procurement mindset is documentation first. Every claim should be checked against records or credible literature.
A practical procurement checklist helps keep the review process consistent. It also reduces the chance that a research buyer will rely on marketing language instead of documentation.
Use this checklist for Cagrilintide research peptide review:
Before ordering research materials, confirm that the product-page listing is complete enough for internal review. The listing should identify the compound, amount, RUO status, documentation availability, and any batch-level records.
If documents are not available on the page, the procurement team should request them before completing the review.
Analytical review should include a method check. HPLC can support purity review, while LC-MS or related mass spectrometry methods can support identity review [4] [11].
A basic lab-test verification protocol can include:
A product-page RUO checklist should ask whether the page stays focused on laboratory research, documentation, analytical testing, and procurement review. It should also ask whether the page avoids personal-use, clinical-use, and outcome-based language.
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
The final review should bring the page back to the same practical question: does the documentation support research procurement? For Cagrilintide, the strongest product-page path includes RUO labeling, COA access, purity data, identity verification, lot traceability, and clear handling and storage documentation.
Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
Lab teams confirm alignment by checking intended-use language, labeling, and internal procurement records. The material should be logged as a research compound and handled according to the lab’s policies.
This step is administrative, but it matters. It keeps the purchase aligned with the research purpose.
Before technical procurement, recheck the product name, lot documentation, analytical method, and COA details. Also confirm that the product page does not rely on unsupported claims.
A well-documented Cagrilintide research peptide page should make this final review simple.
Documentation completes the research buying path because it turns a product listing into a reviewable procurement record. For laboratory research teams, that is the core value of a product-page guide.
Explore Pure Lab Peptides for RUO peptide compounds with research-focused product information and available documentation.
Researchers should consider documentation first before they buy Cagrilintide for research. Key review points include RUO labeling, COA availability, lot traceability, peptide identity, purity data, and supplier documentation. Catalog details should be treated as product listing information only, while scientific literature should remain separate from product claims.
Cagrilintide is discussed in peptide research as a synthetic amylin analogue within metabolic pathway research. Product-page review should focus on compound characterization, peptide structure, research documentation, and analytical testing. Any discussion of receptor signaling should remain tied to published literature and should not become product positioning.
Cagrilintide is of interest in research documentation because it sits within a defined receptor and pathway research lane. Researchers may review characteristics of Cagrilintide, native amylin context, and signaling research to understand literature placement. For procurement, the stronger focus remains COA review, identity confirmation, and lot-level records.
Researchers should evaluate high-purity Cagrilintide claims by checking whether the purity statement is tied to batch-specific documentation. A COA should identify the compound, lot number, testing method, and reported purity. HPLC may support purity review, while LC-MS may support peptide identity review when included in documentation.
Cagrilintide may be studied alongside related compounds to help researchers compare receptor-family context, pathway models, and literature categories. Cagrilintide/semaglutide references should be interpreted only as research literature context. They should not be used to create product claims, product comparisons, or clinical-use positioning for RUO materials.
Cagrilintide product pages stay research-use-only by keeping the focus on compound identity, COA review, analytical testing, lot traceability, RUO labeling, and research documentation. Terms such as appetite regulation, energy balance, body weight, and weight management can drift into consumer-facing claims if not handled carefully. Those terms should remain separated from product positioning.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: ORCID
Kirsten Raun is a scientific author whose publications are relevant to Cagrilintide, amylin analogue research, and metabolic pathway research. Her work helped inform the article’s discussion of Cagrilintide as a synthetic peptide within the broader amylin and calcitonin receptor literature. Her publications also provide useful background for interpreting compound characterization, receptor-family context, and research documentation without converting published literature into product claims.
Selected publications:
Author profile: Monash University Profile
Patrick M. Sexton is a scientific author whose work is relevant to receptor pathway research, calcitonin-family receptor systems, and structural interpretation of peptide-receptor interactions. His publications helped shape the article’s discussion of Cagrilintide receptor context, amylin receptor subtypes, calcitonin receptor systems, and model-specific literature interpretation. This work provides useful background for research-focused discussion of receptor signaling and compound characterization.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Cagrilintide. In metabolic pathway research content, terms such as obesity research, obesity and metabolic research, weight, obesity, medication, satiety, eating, weight loss, hunger, pharmacodynamics, gastrointestinal physiology, and hormone can drift into consumer-facing, wellness, clinical-use, therapeutic-use, or product-claim language when framed incorrectly.
Here, those phrases are handled only as research-language examples, not product uses, outcomes, instructions, or recommendations. The focus remains on Cagrilintide identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, controlled research environments, research settings, and published literature boundaries.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.